A recombinant CYP11B1 dependent Escherichia coli biocatalyst for selective cortisol production and optimization towards a preparative scale by Lina Schiffer et al.
Schiffer et al. Microbial Cell Factories  (2015) 14:25 
DOI 10.1186/s12934-015-0209-5RESEARCH Open AccessA recombinant CYP11B1 dependent Escherichia
coli biocatalyst for selective cortisol production
and optimization towards a preparative scale
Lina Schiffer, Simone Anderko, Anna Hobler, Frank Hannemann, Norio Kagawa and Rita Bernhardt*Abstract
Background: Human mitochondrial CYP11B1 catalyzes a one-step regio- and stereoselective 11β-hydroxylation of
11-deoxycortisol yielding cortisol which constitutes not only the major human stress hormone but also represents a
commercially relevant therapeutic drug due to its anti-inflammatory and immunosuppressive properties. Moreover,
it is an important intermediate in the industrial production of synthetic pharmaceutical glucocorticoids. CYP11B1
thus offers a great potential for biotechnological application in large-scale synthesis of cortisol. Because of its nature
as external monooxygenase, CYP11B1-dependent steroid hydroxylation requires reducing equivalents which are
provided from NADPH via a redox chain, consisting of adrenodoxin reductase (AdR) and adrenodoxin (Adx).
Results: We established an Escherichia coli based whole-cell system for selective cortisol production from 11-
deoxycortisol by recombinant co-expression of the demanded 3 proteins. For the subsequent optimization of the
whole-cell activity 3 different approaches were pursued: Firstly, CYP11B1 expression was enhanced 3.3-fold to
257 nmol∗L−1 by site-directed mutagenesis of position 23 from glycine to arginine, which was accompanied by a
2.6-fold increase in cortisol yield. Secondly, the electron transfer chain was engineered in a quantitative manner by
introducing additional copies of the Adx cDNA in order to enhance Adx expression on transcriptional level. In the
presence of 2 and 3 copies the initial linear conversion rate was greatly accelerated and the final product concentration
was improved 1.4-fold. Thirdly, we developed a screening system for directed evolution of CYP11B1 towards higher
hydroxylation activity. A culture down-scale to microtiter plates was performed and a robot-assisted, fluorescence-
based conversion assay was applied for the selection of more efficient mutants from a random library.
Conclusions: Under optimized conditions a maximum productivity of 0.84 g cortisol∗L−1∗d−1 was achieved, which
clearly shows the potential of the developed system for application in the pharmaceutical industry.
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Cortisol, the major human glucocorticoid, plays a crucial
role in the physiological adaption to stress, the regula-
tion of energy mobilization and immune response [1].
Its anti-inflammatory and immunosuppressive effects
render it a powerful agent for the abatement of classical
inflammatory symptoms like pain or swelling that occur in
the course of acute and chronic inflammatory or auto-
immune diseases. Moreover, cortisol serves as an inter-
mediate in the production of synthetic glucocorticoids,* Correspondence: ritabern@mx.uni-saarland.de
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unless otherwise stated.which can exhibit even greater glucocorticoid effects
but less mineralocorticoid side effects. Prednisolone,
for example, is derived from cortisol by a microbial 1,2-
dehydrogenation [2]. The hydroxyl group in position
11β of the cortisol molecule and its synthetic deriva-
tives is the key functionalization that provides its gluco-
corticoid effects. It is the same functionalization that is
the most difficult one to be introduced chemically or
microbially in the preparative synthesis of cortisol. In
current industrial production it is carried out as the
final step of a hemi synthesis by microbial transform-
ation of 11-deoxycortisol with fungal cultures of the
genus Curvularia in a scale of about 100 tons per year
[3] by taking advantage of the organism’s endogenous. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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process suffers from poor selectivity. Purification and
characterization of the responsible enzyme revealed
low regioselectivity as 11β-hydroxylation of the sub-
strate is accompanied by 14α-hydroxylation [5,6]. Con-
secutively, it is of great interest to develop alternative
biocatalysts for a more selective and efficient introduction
of the 11β-hydroxyl group into synthetic glucocorticoids.
In the human adrenal cortex, which represents the
principal tissue for the biosynthesis and secretion of
gluco- and mineralocorticoids, cortisol is formed select-
ively from 11-deoxycortisol by the 11β-hydroxylase
CYP11B1 (human steroid 11β-hydroxylase) (Figure 1)
[7-10]. Hence, in the context of cortisol production
CYP11B1 also constitutes an attractive candidate for a
biotechnological application.
CYP11B1 belongs to the evolutionary highly conserved
superfamily of cytochromes P450 (P450). P450s catalyze
versatile biotransformations of a wide range of substrates
in all domains of life. It is mainly their capability to acti-
vate molecular oxygen and to incorporate one oxygen
atom into a substrate molecule leading to a regio- and
stereoselective hydroxylation that vests them a tremen-
dous biotechnological potential in the synthesis of phar-
maceuticals and fine chemicals [11-14]. Due to their
nature as external monooxygenases, P450s require an
external electron donor, which is in general NAD(P)H,
and an electron delivering system composed of one or
more additional proteins [15]. In case of CYP11B1,
which represents a mitochondrial P450, the respective
electron transfer chain is constituted of AdR, an NADPH-
dependent flavoprotein, and Adx, a [2Fe-2S]-cluster
protein that interacts with the P450. Such complexity of
P450 systems along with the necessity of a costly cofactor
is so far one of the determining factors that restrict the
employment of P450 catalysts in a larger scale. The most
promising approach to overcome these limitations is the
employment of whole-cell systems that offer cofactors
from their metabolism and a cellular environment for the
support of protein stability and do not require time-
consuming purification steps [12,16]. The current state ofFigure 1 Scheme of the CYP11B1-catalyzed 11β-hydroxylation of 11-d
via AdR and Adx to CYP11B1, which activates molecular oxygen and incorp
hydroxylation in a regio- and stereoselective manner, while the other oxygmolecular biology and recombinant protein expression
enables the exploitation of different microbial hosts for
application of biotechnologically interesting enzymes.
CYP11B1 could already be applied in engineered yeast
strains (Saccharomyces cerevisiae and Schizosaccharo-
myces pombe) that convert 11-deoxycortisol to cortisol
[17-19] or even accept simple carbon sources as substrate
when additional sterol providing and modifying genes are
engineered and introduced [20]. However, optimization of
these systems towards a relevant scale is a great challenge.
Our laboratory previously reported the first expression of
CYP11B1 in a bacterial host (Escherichia coli, E. coli) for
purification and enzymatic characterization [21]. Subse-
quently, we decided to use this fast-growing and genetically
amenable microorganism, which does not possess any en-
dogenous, by-product generating P450s, and established
the first bacterial whole-cell system for application of
CYP11B1 in cortisol preparative scale biosynthesis. The
entire redox chain consisting of AdR, Adx and the P450
was introduced into E.coli. For optimization, CYP11B1
expression was enhanced by site-directed mutagenesis, the
co-expression of Adx was quantitatively adjusted on tran-
scriptional level and CYP11B1 was engineered by molecular
evolution towards higher activity.
Results
Establishment of a CYP11B1 based whole-cell system for
cortisol synthesis in E. coli
In order to employ human CYP11B1 for steroid hydrox-
ylation in E. coli, we created the plasmid Twin_11B1
which is based on the pET-17b vector and carries the
cDNAs of human CYP11B1 including the modifications
described in the Material and methods section, bovine
AdR and bovine Adx in a tricistronic transcription unit
separated by ribosomal binding sites. This enables the
reconstitution of a functional P450 system in the host
organism. The E. coli strain C43(DE3), which has previ-
ously been reported as advantageous for the synthesis of
membrane proteins [22], was co-transformed with the
new plasmid and the chaperone encoding plasmid
pGro12 [23]. Chaperone synthesis supports the propereoxycortisol yielding cortisol. Electrons are transferred from NADPH
orates one oxygen atom into the steroid substrate by means of a
en is reduced to water.
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[21,24-26]. Protein production was carried out in a com-
plex medium and could be confirmed by Western Blot
analysis with primary antibodies raised against CYP11B1,
AdR and Adx, respectively.
Subsequent transformation of 11-deoxycortisol was con-
ducted with non-growing cells in buffer supplemented
with glycerol as carbon source to ensure a sufficient avail-
ability and regeneration of NADPH for the P450 reaction
[27]. Thereby, a fixed cell density of 25 gwcw/L was
adjusted in all experiments. HPLC analysis of extracts
from the resting cells demonstrates a selective CYP11B1
dependent 11β-hydroxylation of 11-deoxycortisol yielding
cortisol (Figure 2). Steroids were identified via their reten-
tion times in comparison with standards from commercial
sources.
As the solubilty of steroidal compounds can be a limit-
ing factor for their bioconversion [12], we subsequently
evaluated the effect of different dissolving agents for the
addition of 11-deoxycortisol on the activity of the new
whole-cell system. Each agent was added to a final con-
centration of 6% (vol/vol). While the employment of
ethanol lead to the lowest cortisol yield and cyclodex-
trines and a 1:1 mixture of EtOH and PEG-400 slightly
improved the final yield, the best results were obtained
with DMSO, which was consecutively used for substrate
supply in all subsequent experiments.
Optimization of CYP11B1 expression
In order to improve the CYP11B1 expression in E. coli
and thus the activity of the recombinant system, weFigure 2 HPLC chromatogram of the CYP11B1 dependent
conversion of 11-deoxycortisol to cortisol by recombinant E.
coli. Chromatograms were obtained from extracted samples of E.
coli cultures after 0 h (dotted line) and 24 h (solid line) of incubation
after transfer into potassium phosphate buffer and addition of
1.2 mM substrate. Substance peaks obtained with an acetonitrile/
water gradient represent cortisol with a retention time of 9.0 min
and 11-deoxycortisol with a retention time of 14.3 min.performed site-directed mutagenesis in position 23 of
the E. coli adapted sequence. Glycine, which corresponds
to the published wildtype amino acid in that position
[28,29], was replaced by the hydrophilic amino acid ar-
ginine. An analogous replacement from glycine to argin-
ine, which was introduced into human CYP19 when
performing N-terminal replacements with related se-
quences from other P450s by Kagawa et al. [30], was re-
ported to significantly enhance the expression in E. coli.
The corresponding residue in human CYP11B1 was
identified by primary sequence alignment. The expres-
sion level of the 2 CYP11B1 variants was estimated by
CO-difference spectroscopy (Figure 3). The introduction
of the arginine residue could succesfully enhance
CYP11B1 level from 79 to 257 nmol∗L−1 and no signifi-
cant reduction over the conversion period could be
observed.
Cortisol formation by both enzyme variants in the
whole-cell system was monitored in a time-dependent
manner. In general, the system exhibited a linear volu-
metric productivity in an initial phase of at least 12 h.
Afterwards the velocity of cortisol formation decreased
and a final product concentration was reached after
30 h. The deployment of CYP11B1 G23R for the whole-
cell conversion of 11-deoxycortisol increased the final
cortisol yield after 30 h by a factor of 2.6 compared with
the G23 variant from 239 to 631 mg∗L−1 (Figure 4). The
initial linear productivity was enhanced in the same
range from 11 to 27 mg∗L−1∗h−1. Therefore, CYP11B1
G23R is applied for all further experiments and will beFigure 3 Expression level of CYP11B1 enzyme variants carrying
either glycine (G23) or arginine (G23R) in position 23. Recombinant
E. coli cultures expressing either wild type or mutant were harvested
after the expression period (white bars) or at the end of substrate
conversion (grey bars) under the conditions described in Material
and methods. P450 concentration was determined by CO-difference
spectroscopy with the supernatant of the cell lysate after
ultracentrifugation. Values represent the mean of three experiments
with the respective standard deviation.
Figure 4 Comparison of the whole-cell cortisol formation by
CYP11B1 enzyme variants carrying either glycine (G23) or
arginine (G23R) in position 23 in recombinant E. coli. Reactions
were performed after a 21-h expression period in TB medium with
resting cells in the presence of 6% DMSO and 3 mM 11-deoxycortisol.
Extracted steroids were analyzed by RP-HPLC. Values represent the
mean of three conversion experiments conducted in parallel with
respective standard deviation.
Figure 5 Western blot analysis of Adx expression by recombinant
E. coli cells. Lane 1 shows purified bovine Adx4–108 (~11,8 kDa). lane 2
shows a pre-stained protein marker with molecular weights indicated
on the left of the picture. Lanes 3 to 6 represent the lysate of E. coli cells
expressing the CYP11B1 redox system from variants of the Twin_11B1
plasmid carrying 1 to 4 copies of bovine Adx1–108 (~12,0 kDa).
Adx detection was carried out with polyclonal antibodies and a
peroxidase-based color reaction. The relative expression level of
Adx was determined by measuring the band intensity with the
Image Lab software.
Figure 6 Comparison of the cortisol formation by recombinant
E. coli transformed with different versions of the P450 system
encoding plasmid Twin_11B1 with 1 (circles), 2 (squares) or 3
(triangles) copies of the Adx cDNA. Reactions were performed after
a 21-h expression period in TB medium with resting cells in the presence
of 6% DMSO and 3 mM 11-deoxycortisol. Extracted steroids were
analyzed by RP-HPLC. Values represent the mean of three conversion
experiments conducted in parallel with respective standard deviation.
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lecular evolution studies.
Influence of Adx copy number
As electron supply frequently constitutes the limiting
step in the efficiency of P450 systems [31-33], our next
approach for improving the whole-cell activity of
CYP11B1 was an increase of the amount of Adx in the
system, in order to enhance electron transfer to
CYP11B1. For that, we constructed variants of the ex-
pression plasmid Twin_11B1 with up to 4 copies of the
Adx cDNA by successively integrating additional copies
including a 5′-ribosomal binding site at the end of the
trancription unit according to Blachinsky et al. [34]. The
relative increase of Adx expression was estimated by
Western Blot (Figure 5) and evaluation of the Adx signal
with an imaging software. With the introduction of a
second cDNA copy Adx expression was increased ap-
proximately 2.4-fold and a maximum of Adx expression
(3.3-fold increase) was reached with the insertion of a
third copy which could not be further augmented by a
fourth copy. No influence on CYP11B1 expression was ob-
served by CO-difference spectroscopy, when 2 or 3 copies
of Adx were present on the expression vector. With the
insertion of a fourth Adx copy, the CYP11B1 titer was,
however, reduced by 50% to approximately 120 nmol∗L-1
and the construct was thus not further investigated.
Subsequent whole-cell conversions conducted with 2
and 3 Adx copies increased the final product concentra-
tion from 631 mg∗L−1 for the initial system with 1 Adx
to 877 and 828 mg∗L−1, respectively (Figure 6).Although both plasmids enabled a comparable final
yield, the presence of 2 Adx copies also greatly enhanced
the initial productivity over the first 12 h from 27 to
52 mg∗L−1∗h−1, while a third copy diminished this rate
again to 37 mg∗L−1∗h−1 but exhibited a longer phase of
linearity in time-dependent product formation leading to
a comparable final yield.
Development of a screening system for CYP11B1 activity
For further improvement of the CYP11B1 activity using
molecular evolution, we adapted the biotransformation
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evaluation to a microtiter plate format which enables a
high and robot-assisted throughput. Culture size was
scaled down to 1 mL and substrate conversion was car-
ried out in TB medium with inoculation, induction of
protein expression and addition of the substrate 11-
deoxycortisol at the same time in order to reduce work-
ing steps to a minimum. For evaluation of enzyme activity,
we employed a fluorescence assay, which makes use of the
fluorescence developed by steroids with an intensity in de-
pendence on the substitution of the steran scaffold
[35-37]. As cortisol exposes a higher fluorescence than 11-
deoxycortisol due to the additional hydroxyl group that is
introduced in position 11β, enzyme variants with an in-
creased hydroxylation activity can easily be selected. In
order to ensure optimal conditions for the detection of
mutants with improved activity, conversion with the par-
ental enzyme variant Pa1 (CYP11B1 G23R) was tested
with different substrate concentrations and the fluores-
cence was determined after 48 h of incubation in compari-
son with control cultures that were incubated with the
respective 11-deoxycortisol concentration but without in-
duction of protein expression. A clear difference between
unspecific and steroid specific fluorescence could be
observed as well as a significant increase of the relative
fluorescence by a factor of more than 3 upon induction
of protein expression, which proofs the presence of an
active P450 system and thus the applicability of the sys-
tem for monitoring 11-deoxycortisol conversion to cor-
tisol (Figure 7).Figure 7 Relative fluorescence developed by recombinant E.
coli cultures after incubation with different 11-deoxycortisol
concentrations. Cells were transformed with Twin_11B1 and
pGro12 and incubated with 11-deoxycortisol for 48 h in TB medium
containing 1 mM δ-Ala (white bars) that has been additionally
supplemented with 1 mM IPTG and 4 mg/mL arabinose for induction
(grey bars). Steroid specific fluorescence was generated by the
described assay and measured in relative units (R.F.U.) at λex
485 nm and λem 535 nm. Values represent the mean of triplicates
with standard deviations.Higher substrate concentrations result in an increased
activity, which is displayed by an increased fluorescence
signal and which was confirmed by HPLC analysis. Ste-
roids were identified by their retention time and relative
quantification depicted 20.2 ± 2.9% conversion of 11-
deoxycortisol to cortisol at a concentration of 400 μM,
which was subsequently chosen for the selection of ac-
tivity improved mutants.
Generation and screening of a CYP11B1 mutant library
A random CYP11B1 mutant library was created by
epPCR applying the sequence of CYP11B1 Pa1 as a tem-
plate. The emerged sequence variants were cloned into
the Twin plasmid and C43(DE3) E. coli cells were co-
transformed with the mutant Twin_11B1 plasmid library
as well as pGro12 and were spread on agar plates. Se-
quencing of 10 randomly picked clones revealed a muta-
tional frequency of 2.83 base exchanges per kilobase.
Approximately 1000 clones were screened with the
fluorescence assay for enhanced hydroxylation activity
towards 11-deoxycortisol. From these, 53 clones, which
exhibited an at least 1.5-fold higher fluorescence signal
than the CYP11B1 Pa1 control incubated on the same
plate, were re-screened in triplicates. For 3 mutants,
which still showed an average increase of the fluores-
cence signal by more than the 1.5-fold, an activity in-
crease between the 1.7- and 2.4-fold under screening
conditions could be confirmed by HPLC. Sequencing
identified the amino acid replacements H171L, Q166R/
L271M and S168R/M286I/Q315E, respectively, for the
selected clones. For the identification of the residues
which cause the increased activity in case of the double
and triple mutant all observed exchanges were intro-
duced separately into CYP11B1 Pa1 by site-directed mu-
tagenesis and analyzed for their whole-cell activity in
microtiter plates using HPLC. Their activities regarding
cortisol formation in comparison with the CYP11B1 Pa1
enzyme are shown in Figure 8.
The amino acid exchange Q166R, which occurred in the
double mutant Q166R/L271M, reduced the CYP11B1 ac-
tivity to about 50% when introduced individually. The re-
moval of this unfavorable exchange leading to the single
mutant L271M increased activity of CYP11B1 Pa1 ap-
proximately 3.4-fold. Two of the exchanges of the triple
mutant, S168R and Q315E, did not show any or only a
slightly beneficial effect on product formation, while the
third exchange, M286I, alone enhanced product formation
by a factor of 2.7 compared with CYP11B1 Pa1, which
represents an additional slight increase compared with the
parental triple mutant. The best mutant, L271M, was
chosen for subsequent experiments. No significant differ-
ences in expression level in the microtiter plate were ob-
served between CYP11B1 Pa1 and L271M, which were
synthesized with 57 and 69 nmol∗L−1, respectively. This
Figure 8 Relative cortisol formation of CYP11B1 enzyme
variants in microtiter plates evaluated by HPLC. Mutants H171L,
Q166R/L271M and S168R/M286I/Q315E were selected in the
fluorescence based screening of a random mutant library. All other
mutants were created by site-directed mutagenesis. Conversion took
place for 48 h as described under Material and methods with 400 μM
11-deoxycortisol and cortisol formation was evaluated by HPLC and is
presented in a relative manner as mean of triplicates with respective
standard deviation. Product formation of CYP11B1 Pa1 was assigned as 1.
Figure 9 Time-dependent whole-cell cortisol formation by the
parental CYP11B1 enzyme (Pa1) and the selected mutant
L271M in shaking flasks. Pa1 (black circles) was expressed from
the Twin_11B1 plasmid carrying 1 Adx copy, while L271M was
expressed from plasmids with either 1 Adx (grey cirlces) or 3 Adx
(grey triangles) copies. Reactions were performed after a 21-h expression
period in TB medium with resting cells in presence of 6% DMSO and
3 mM 11-deoxycortisol. Extracted steroids were analyzed by RP-HPLC.
Values represent the mean of three conversion experiments conducted
in parallel with respective standard deviation.
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hanced product yield.
Large-scale cortisol production by the selected CYP11B1
mutant
In order to verify the reliability of the microtiter plate
screening for activities in larger scale, mutant L271M
was analyzed for its time-dependent capacity of cortisol
formation with resting cells in shaking flasks as de-
scribed in Material and methods. As expected, the mu-
tant turned out to be more productive than its parent
CYP11B1 Pa1 and its application enabled an increase of
the final product concentration from 631 to 777 mg∗L−1
(Figure 9). The expression level of L271M in shaking
flasks was ascertained as approximately 240 nmol∗L−1
and is thus comparable to the expression level of
CYP11B1 Pa1. Moreover, we combined the mutant in a
plasmid with 3 Adx copies, as this number maximized
Adx synthesis in the preceding experiments. This com-
bination revealed an additive effect during the initial
phase of the reaction and the productivity of L271M
over the first 12 h was stimulated by the enhanced Adx
availability in a dimension comparable to the effect of 3
Adx copies on CYP11B1 Pa1, leading from 38 to
48 mg∗L−1∗h−1 (Figure 9).
Discussion
CYP11B1, which synthesizes cortisol from 11-deoxycortisol
in the human adrenal cortex, also exposes a great potential
as biocatalyst in the industrial synthesis of cortisol, apharmaceutically and thus commercially important steroid
due to its anti-inflammatory and immunosuppressive ef-
fects. In this work, the successful reconstitution of a
CYP11B1 system in a recombinant E. coli whole-cell biocat-
alyst, which is capable of forming cortisol from 11-
deoxycortisol by 11β-hydroxylation, is presented. Because
of the selectivity of 11-deoxycortisol hydroxylation by
CYP11B1 in combination with a high volumetric productiv-
ity and the absence of side-product formation by E. coli, the
developed system provides distinct advantages over other
bioprocesses that have been established for cortisol produc-
tion. Current industrial synthesis from 11-deoxycortisol by
means of an 11β-hydroxylation via biotransformation by
the fungus C. lunata [4] is accompanied by side-product
formation [6], while alternative systems in recombinant
yeast suffer from poor efficiencies [17-20]. Figure 10
compares the volumetric productivities [mg∗L−1∗d−1]
of publically accessible systems for cortisol production
by CYP11B1 dependent biotransformation. Our new E.
coli based system, which enabled a maximum volumet-
ric productivity of 843 mg∗L−1∗d−1, exhibits a product-
ivity which is nearly one order of magnitude higher
than the best value published. In order to realize this,
strategies have been developed to successfully target
factors which frequently limit the application of P450s
in industrial biocatalysis.
Recent studies hint at a favorable effect of N-terminal
replacements of hydrophobic amino acids by positively
charged ones for the expression and stability of
eukaryotic P450s in E. coli [30,38]. The introduction of a
Figure 10 Comparison of the volumetric productivities of
publically available CYP11B1 dependent whole-cell biocatalysts
for cortisol production. The respective publications as well as the
host organisms and the substrates are indicated.
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by site-directed mutagenesis of position 23 from glycine
to arginine greatly enhanced the expression level, while
maintaining catalytic activity, and thus improved initial
productivity as well as the final product yield by a factor
of 2.6.
After successfully increasing CYP11B1 expression, our
second aim was an optimization of the electron flux
from cellular NADPH towards CYP11B1 by engineering
the redox chain which is reconstituted in E. coli by co-
expressing AdR and Adx with the P450 from a tricistro-
nic plasmid. Especially the electron transfer from Adx to
the P450 is known to be an activity limiting step in P450
catalysis, which can be at least partially rescued by trun-
cation and mutagenesis of Adx [31,32] or by increasing
the Adx availability in the system which could already be
demonstrated for CYP11B1 in in-vitro experiments with
purified enzymes [21,39], as well as in recombinant cell
cultures [40] and yeast [19]. In-vitro studies proof a de-
pendency of CYP11B1 activity on Adx concentration fol-
lowing the Michealis-Menten equation at a stable AdR
concentration [21] and describe that upon excess of Adx
the maximum CYP11B1 hydroxylation activity is already
achieved at molar ratios of AdR/CYP11B1 lower than 1
[41-43]. Additionally, investigations of a class I P450
system reconstituted in E. coli show a ratio for P450:
ferredoxin:reductase of 1:6:1 under expression conditions
optimized for substrate hydroxylation with CYP105A1
[44]. Therefore, we decided to engineer the ratio of
CYP11B1 to Adx expression and introduced additional
copies of the Adx cDNA into the polycistronic expression
unit in order to enhance Adx expression on transcrip-
tional level and to reduce the rate-limiting factor of Adx
availability in the E. coli biocatalyst. The approach suc-
ceeded to improve the productivity to a maximumpossible within the polycistronic transcriptional strategy.
Initial productivity was greatly accelerated and the final
product concentration was increased by a factor of 1.4 at
the maximum Adx level. This indicates that the limita-
tions of the whole-cell activity caused by a reduced Adx
availability were successfully overcome by the presented
approach. Moreover, the high Adx concentration might
have a general positive effect on the viability of the whole-
cells as the [2Fe-2S]-cluster can function as a scavenger by
trapping reactive oxygen species [45] which can be formed
in the course of the P450 catalytic cycle [11].
In a parallel approach for the optimization of the whole-
cell activity, new CYP11B1 variants with an increased ac-
tivity of cortisol formation from 11-deoxycortisol were
generated. Directed evolution, which consists of one or
several cycles of enzyme mutagenesis, screening for the
desired enzyme properties and selection of favorable mu-
tants, represents a classical tool for such kind of enzyme
engineering towards improved catalytic efficiencies, re-
duced uncoupling, altered selectivity or substrate specifi-
city [46]. However, the crucial step in the establishment of
a system for directed evolution is the development of a
screening assay which enables a sensitive and accurate se-
lection of the desired enzyme features with a high
throughput. In order to meet these criteria, we performed
a down-scale of the steroid-converting E. coli system to
microtiter plates and employed a fluorescence based activ-
ity assay [35] in a robot-assisted manner. This assay has
already been successfully applied for the improvement of
the catalytic activity of CYP106A2 from Bacillus megater-
ium towards its steroidal substrates 11-deoxycortisol and
progesterone [37,47]. It is premised on the fluorescence
developed by steroids in an acidic, hygroscopic environ-
ment whose intensity can vary between substrate and
product of a hydroxylation reaction. This is true for the
transformation of 11-deoxycortisol to cortisol in the pre-
sented E. coli system with increasing fluorescence intensity
upon formation of cortisol which proofs the applicability
of the assay for the detection of activity enhanced mutants.
Because of the little information about structure-activity
relation of adrenocortical P450s in the literature, we con-
ducted a random PCR mutagenesis of the entire CYP11B1
gene and examined the arising mutant library with the
fluorescence screening test. We were able to select 3 mu-
tants, H171L, Q166R/L271M and S168R/M286I/Q315E,
that exhibited an approximately 2-fold increased activity
in the microtiter scale and retained selectivity as shown by
HPLC measurements. The activity improvements mea-
sured via fluorescence screening in the microtiter plates
were supported by HPLC analysis underlining reliability of
the screening procedure. The predicted localizations of
mutated residues are summarized in Table 1.
The subsequent individual analysis of amino acid ex-
changes from the double and triple mutant revealed
Table 1 Localization of amino acid exchanges of CYP11B1
mutants with increased activity
Amino acid exchange Localization
H171L E’-helix, protein surface
Q166R E’-helix, protein surface
L271M H-helix, protein surface
S168R E’-helix, protein surface
M286I I-helix
Q315E J-helix, protein surface
Localization of the respective residues discovered during the screening of a
random CYP11B1 library for mutants with increased 11β-hydroxylation activity
towards 11-deoxycortisol was deduced from the latest homology model of
CYP11B1 [25].
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positive charge into the E’-helix (S168R, Q166R), while
the elimination of a potentially positively charged resi-
due (H171L) increases the CYP11B1 activity. The re-
moval of the unfavorable mutations further enhanced
cortisol formation up to 3.4-fold compared with Pa1,
when using L271M or M286I. L271M, a conservative ex-
change which is predicted to be localized in the H-helix
on the protein surface (Figure 11), was identified as the
exchange that contributes most efficiently to CYP11B1
activity. As the H-helix represents the link between the
I-helix which traverses the active site and the mobile
F/G-loop, which is involved in substrate access to the
active site [48], the slight alteration in the residue’s
physicochemical properties might positively influence
the flexibility of CYP11B1. M286I, the second activity
increasing amino acid replacement, resides in the I-
helix (Figure 11). It is not part of the active site pocket
but can be assumed to strengthen structural integrityFigure 11 Localization of amino acid exchanges of CYP11B1
that increase hydroxylation activity towards 11-deoxycortisol.
L271M is located on the protein surface in the H-helix, while M286I
resides in the I-helix. Helices are labeled with their eponymous letter.
The structure represents the latest homology model [25] and figures
were created with PyMOL Builds. Mutated amino acids and the
heme are highlighted in black.of this core element. Q315E leads to the introduction
of a charged group in the J-helix on the protein surface
and does not have significant impact on the CYP11B1
activity which identifies M286I as determining muta-
tion for the selection of the triple mutant. An upscale
of the system from microtiter plates to shaking flasks
using the most efficient mutant, L271M, could suc-
cessfully reproduce the improvement of the whole-cell
activity and enhanced the initial productivity as well as
the final product concentration in comparison to
CYP11B1 Pa1. The proposed screening procedure can
thus be regarded as reliable for the optimization of
large-scale processes by laboratory evolution. The mu-
tagenesis approach can be combined with the strategy
of engineering the redox partner co-expression leading
to additive effects (Figure 9). However, the activity of
all systems flattens after approximately 24 h and can-
not be rescued with the approaches presented in this
work. This points at the necessity of further optimization
on the levels of process and strain engineering.Conclusions
Taken together, we report the establishment of an E. coli
based biocatalyst for cortisol production by a heterol-
ogous CYP11B1 system, which enables a maximum
productivity of 0.84 g∗L−1∗d−1 under simple shaking
flask conditions and thus clearly meets efficiency re-
quirements for potential application in the pharmaceutical
industry [49,50]. In total, our optimization approaches
could increase the cortisol yield by a factor of 3.7. The pre-
sented strategy to overcome activity limits due to low pro-
tein ratios of Adx to CYP11B1 can be transferred to other
biotechnologically interesting P450 redox chains in whole-
cell application as Adx represents an efficient electron
transfer partner not only for mitochondrial but also for
microsomal and bacterial P450s [31,51]. The successful es-
tablishment of an accurate and fast screening system for
CYP11B1 activity in combination with new structure-
activity insights from the first mutant generation can be
used for further directed evolution of the enzyme [52].
The system might additionally be applicable for the
screening of CYP11B1 inhibitors, which can be important
drugs for the treatment of for example Cushing’s syn-
drome [53].Material and methods
Chemicals and enzymes
All chemicals and reagents were purchased from stand-
ard sources in the highest purity available. Restriction
enzymes were obtained from New England Biolabs
(Ispwich, MA, USA), Pfu polymerase from Promega
(Madison, WI, USA), and FastLink Ligase from Epi-
centre Biotechnologies (Chicago, IL, USA).
Schiffer et al. Microbial Cell Factories  (2015) 14:25 Page 9 of 12Bacterial strains and cultivation
Plasmid construction was performed with E. coli
TOP10F’ (F-mcrA (mrrhsdRMS-mcrBC) f80lacZDM15
DlacX74 deoR recA1 araD139 (ara-leu)7697 galU galK
rpsL (StrR) endA1 nupG). All experiments involving pro-
tein expression and steroid conversion were conducted
with E. coli C43(DE3) (F– ompT gal hsdSB (rB- mB-)
dcm Ion λ). Transformation was carried out by electro-
poration and transformed cells were stored on agar
plates supplemented with the appropriate antibiotics
(100 μg/mL ampicillin and/or 50 μg/mL kanamycin) at
4°C.
Plasmid construction and mutagenesis
All methods of molecular biology were performed ac-
cording to standard protocols described by [54]. The
plasmid Twin_11B1 served as template for the prepar-
ation of all further plasmids. It is based on the pET-17b
expression vector (MerckMillipore Novagen, Darmstadt,
Germany), which enables a selection on ampicillin con-
taining medium, and carries the cDNAs of human
CYP11B1 cloned into the vector via NdeI/HindIII, bo-
vine AdR via HindIII/KpnI and bovine Adx1–108 via
KpnI/EcoRI in a polycistrionic transcription unit [55].
CYP11B1 was modified for expression in E. coli as de-
scribed by [21]. Additionally, residue 29 in the E. coli
adapted sequence (corresponding to residue 52 in the
full length sequence) is mutated from leucine to methio-
nine taking previous activity studies in recombinant fis-
sion yeast [19] into account. All utilized primers are
shown in Additional file 1: Table S1.
Insertion of additional gene copies
In order to consecutively insert additional copies of the
Adx cDNA into the Twin_11B1 plasmid behind the pre-
existing copy, the following strategy, which takes advan-
tage of restriction site compatibility of EcoRI and MfeI,
was pursued referring to [34]. In a first step, Twin_11B1
was used as a template to amplify the Adx cDNA by
PCR including its ribosomal binding site and to intro-
duce MfeI and XhoI restriction sites at the 5′ and 3′
end, respectively. The PCR product was then digested by
MfeI and XhoI and ligated into the EcoRI/XhoI digested
Twin_11B1 plasmid resulting in a plasmid carrying 2
Adx copies. In additional cycles of restriction and
ligation further copies were inserted. In subsequent
cloning attempts inserts of different Adx copy numbers
could then be introduced into new plasmids by restric-
tion and ligation via KpnI and EcoRI.
Site directed mutagenesis of CYP11B1
Targeted exchange of single amino acids was undertaken
by QuikChange® mutagenesis with Pfu polymerasefollowing manual instructions form Agilent Technolo-
gies (Santa Clara, USA).
Random mutagenesis of CYP11B1
Random mutagenesis of CYP11B1 was conducted by
error prone PCR employing the GeneMorph II random
mutagenesis kit (Stratagene, La Jolla, CA, USA).
pET17b_hCYP11B1, which contains the modified cDNA
of human CYP11B1 between the NdeI and HindII re-
striction sites of its multiple cloning site, was used as a
template for the amplification of CYP11B1 with the
standard primers T7 and T7term. Parameters for an
average mutation frequency of 0–3 mutations per kb
were chosen according to the manufacturer’s protocol.
The PCR product was digested by NdeI and HindIII and
ligated into the likewise digested Twin_11B1 plasmid.
Whole-cell biocatalysis in shaking flasks
Protein expression
The synthesis of CYP11B1, AdR and Adx in E. coli took
place as co-expression with the chaperone genes GroEL
and GroES to ensure proper folding. Protein synthesis
was carried out in 2 L Erlenmeyer flasks containing
150 mL TB medium (24 yeast extract technical, 12 g
peptone, 4 mL glycerol, 4,62 g KH2PO4, 25 g K2HPO4
and distilled water ad. 1 L) supplemented with 100 μg/mL
ampicillin and 50 μg/mL kanamycin. The main culture
was inoculated from an overnight culture of E. coli C43
(DE3), that had been freshly co-transformed with the re-
spective variant of Twin_11B1 and the chaperone vector
pGro12 (kanamycin resistance and arabinose inducible
promoter) [23], and was grown at 37°C and 210 rpm
(Excella 25 shaker incubator, New Brunswick Scientific,
Eppendorf, Ensfield, CT, USA). When an OD600 nm of 0.5
was reached expression was induced by addition of 1 mM
IPTG, 4 mg/mL arabinose, 1 mM of the heme precursor
δ-aminolevulinic acid and 50 μg/mL ampicillin. Cultures
were further incubated at 27.5°C and 200 rpm for 21 h.
Steroid conversion with resting cells
Subsequent to the expression period cultures were har-
vested by centrifugation (3200 g, 10 min, 18°C) and cells
were washed in 50 mM potassium phosphate buffer
(pH 7.4). Steroid conversion took place at 27.5°C and
170 rpm in 300-mL baffled flasks using 25 mL of a cell
suspension of 25 g wet cell weight (wcw) per L in
50 mM potassium phosphate buffer (pH 7.4) supple-
mented with 1 mM IPTG, 4 mg/mL arabinose, 1 mM δ-
aminolevulinic acid, 50 μg/mL ampicillin and 2% glycerol.
The substrate 11-deoxycortisol (17,21-dihydroxypregn-4-
ene-3,20-dione) was added from a stock solution in
either EtOH, DMSO, 22.5% (m/vol) 2-hydroxypropyl-β-
cyclodextrin or a 1:1 (vol:vol) mixture of EtOH and
polyethyleneglycol-400. Each agent was added to the
Schiffer et al. Microbial Cell Factories  (2015) 14:25 Page 10 of 12culture in a final concentration of 6% (vol/vol). Samples
were taken at defined time points.
Reversed phase HPLC analysis
For product quantification via HPLC, samples were ex-
tracted twice with one volume of chloroform. After
evaporation of the organic solvent remaining steroids
were suspended in acetonitrile and separated on a Jasco
reversed phase HPLC system of the LC900 series (Jasco,
Groß-Umstadt, Germany) using a 4.6 m × 125 mm
NucleoDur C18 Isis Reversed Phase column (Macherey-
Nagel, Düren, Germany) with an acetonitril/water gradi-
ent (Phase A: 10% acetonitrile, Phase B: 100% acetonitril;
0 min 20% B, 5 min 20% B, 13 min 40% B, 20 min 80%
B, 21 min 80% B, 22 min 20% B, 30 min 20% B) at 40°C
and a flow rate of 0.8 mL/min. Steroid pattern was mon-
itored by an UV/Vis detector (UV-2 075 Plus, Jasco) at
240 nm.
Screening for improved CYP11B1 activity in microtiter
plates
Protein expression and steroid conversion in microtiter
plates as well as a fluorescence assay for the selection of
CYP11B1 mutants with an improved hydroxylation ac-
tivity towards 11-deoxycortisol was performed as previ-
ously reported [36], but TB medium was additionally
supplemented with 50 μg/mL kanamycin and 4 mg/mL
arabinose to ensure chaperone synthesis from pGro12
and did not contain a salt solution.
Analysis of protein expression
Cell lysis
For the analysis of CYP11B1 expression levels cells were
harvested by centrifugation (4500 g, 20 min, 4°C), sus-
pended in lysis buffer (50 mM potassium phosphate buffer
(pH 7.4), 500 mM sodium-acetate, 0.1 mM EDTA, 1.5%
sodium-cholate, 20% glycerol, 1.5% Tween 20, 0.1 mM
phenylmethylsulfonylfluorid and 0.1 mM dithioerythritol)
and disrupted with an ultrasonic homogenizer (Sonopuls
HD 3200, Bandelin, Berlin, Germany). Cell debris were re-
moved by ultracentrifugation (30000 g, 30 min, 4°C; hinac
CP75, Hitachi, Tokyo, Japan) and the supernatant was sur-
veyed for recombinant proteins.
Determination of cytochrome P450 concentration
P450 concentration was determined by CO-difference
spectroscopy using a molar extinction coefficient of
91 mM−1 cm−1 as described by [56].
Western blot analysis of Adx synthesis
Cell pellets from 90 μL of the 25gwcw/L cell suspension
were suspended in 100 μL of SDS loading buffer (1 M
Tris–HCl (pH 6.8), 40% glycerol, 20% SDS, 8% β-
mercaptoethanol, 0.1% bromphenol blue) and boiled for10 min in a water bath. Aliquots of 12 μL were separated
by SDS-PAGE according to [57]. 8 μL of a 5 μM solution
of purified bovine Adx4–108 in SDS loading buffer were
applied as positive control and Protein Marker IV from
PEQLAB (Erlangen, Germany) served as molecular
weight standard. Proteins were blotted onto a hybond™
ECL™ nitrocellulose membrane (Amersham, GE Health-
care, UK) with the help of a semi-dry transfer system
(Trans-Blot SD, Bio-Rad, Munich, Germany) and the
membrane was blocked by incubation with 3% milk
powder in TBS (50 mM Tris–Cl pH 7.4, 200 mM NaCl,
0.1% Tween 20) overnight. The membrane was washed
3 times for 10 minutes in fresh TBS and was incubated
for 2 h with the respective polyclonal antiserum from
rabbit diluted in TBS. Subsequent to 3 further washing
steps in TBS the membrane was incubated for 2 h with
a dilution of the horseradish peroxidase-linked goat
anti rabbit IgG secondary antibody (Dako, Glostrup,
Denmark) in TBS. After washing the membrane 3 times
for 5 minutes with PBS (10 mM potassium phosphate
buffer pH 7.4, 150 mM NaCl) staining of the antigen-
antibody-complexes took place by adding 5 mg 4-chloro-
1-naphtol dissolved in 2 mL ethanol and 10 μL 30% H2O2
in 25 mL PBS. Relative intensity of the protein bands was
measured with Image Lab 3.0 from BioRad (München,
Germany).
Additional file
Additional file 1: Table S1. Primers used in this work with sequence
and purpose of application. Restriction sites are marked with bold letters,
introduced nucleotide exchanges are underlined.
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